Octapharma USA announced that Nuwiq (antihemophilic factor [recombinant]) is now available for the treatment and control of bleeding, perioperative management, and routine prophylaxis to reduce bleeding episodes in patients with hemophilia A. The treatment was initially approved by the Food and Drug Administration (FDA) in September 2015.
Nuwiq is the first 4th generation recombinant Factor VIII derived from a human cell-line without any chemical modification or protein fusion. Nuwiq temporarily replaces the missing clotting Factor VIII that is needed for effective hemostasis.
Nuwiq is available as packages of single-use vials containing nominally 250 IU, 500 IU, 1000 IU, or 2000 IU of Factor VIII potency. Each package contains a prefilled syringe of solvent, a vial adapter, a butterfly needle, and alcohol swabs.
For more information call (866) 766-4860 or visit Nuwiq.com.